Amgen names Peacock chief financial officer – The Associated Press
By Dr. Matthew Watson
![]() RTT News | Amgen names Peacock chief financial officer The Associated Press Biotechnology company Amgen Inc. said Thursday it named Novartis executive Jonathan M. Peacock as its new chief financial officer. ... Amgen names Novartis finance executive to be CFOReuters Amgen Names Novartis Exec Jonathan Peacock New CFORTT News Amgen names Peacock chief financial officerNewsday (subscription) One News Page -Los Angeles Business -PR Newswire (press release) all 145 news articles » |
Vivus: An Option Pricing Case Study – Seeking Alpha (blog)
By Dr. Matthew Watson
![]() RTT News | Vivus: An Option Pricing Case Study Seeking Alpha (blog) Trading in Vivus (VVUS) was halted this morning, as the biotechnology company's new weight-loss pill, Qnexa, is being reviewed by a panel of experts at the ... Obesity Drug Fails To Win FDA Panel OkayOzarksFirst.com (blog) Vitamin maker NYBT acquired for $3.8 billion. After the bell: VIVUS shares ...BioMedReports (subscription) Weight-loss drug Qnexa gets thumbs-down from FDA panelLos Angeles Times BusinessWeek -Wall Street Journal -MarketWatch all 450 news articles » |
DNA Drugs Come of Age (preview)
By Dr. Matthew Watson
In a head-to-head competition held 10 years ago, scientists at the National Institutes of Health tested two promising new types of vaccine to see which might offer the strongest protection against one of the deadliest viruses on earth, the human immunodeficiency virus (HIV) that causes AIDS. One vaccine consisted of DNA rings called plasmids, each carrying a gene for one of five HIV proteins. Its goal was to get the recipient’s own cells to make the viral proteins in the hope they would provoke protective reactions by immune cells. Instead of plasmids, the second vaccine used another virus called an adenovirus as a carrier for a single HIV gene encoding a viral protein. The rationale for this combination was to employ a “safe” virus to catch the attention of immune cells while getting them to direct their responses against the HIV protein.
One of us (Weiner) had already been working on DNA vaccines for eight years and was hoping for a major demonstration of the plasmids’ ability to induce immunity against a dreaded pathogen. Instead the test results dealt a major blow to believers in this first generation of DNA vaccines. The DNA recipients displayed only weak immune responses to the five HIV proteins or no response at all, whereas recipients of the adenovirus-based vaccine had robust reactions. To academic and pharmaceutical company researchers, adenoviruses clearly looked like the stronger candidates to take forward in developing HIV vaccines.
Immune system - National Institutes of Health - Vaccine - HIV - DNA
Innovative Researcher Vlog
By Dr. Matthew Watson
SU2C Innovative Researcher Vlog: Dr. Lawlor (Pt. 3). Video (3:09 min) posted July 13, 2010. Features Elizabeth R Lawlor, University of Michigan, an SU2C Innovative Research Grants Investigator. [About SU2C (Stand Up to Cancer)]. She provides brief comments about her project: "Modeling Ewing Tumor Initiation in Human Neural Crest Stem Cells". How do normal stem cells become cancer stem cells?
An example of a recent (OA) publication from her laboratory: CD133 expression in chemo-resistant Ewing sarcoma cells by
Xiaohua Jiang and 8 co-authors, including Elizabeth R Lawlor,
BMC Cancer 2010(Mar 26); 10: 116. [FriendFeed entry][PubMed citation][Full text via PMC].
Investors welcome uptick in venture capital so far this year – Seattle Times
By Dr. Matthew Watson
![]() Bizjournals.com | Investors welcome uptick in venture capital so far this year Seattle Times Biotechnology was the top industry nationally, receiving $1.30 billion. The clean-technology sector — composed of a number of industries, ... Venture funding slips in NE in latest quarterBoston Globe VCs invest $6.5 billion nationally in 2QBizjournals.com Venture-capital funding in Colo. lowest since 1996Denver Post Investor's Business Daily -TechCrunch (blog) all 25 news articles » |
UMass wins $20m ‘bench to bedside’ grant – Boston Globe (blog)
By Dr. Matthew Watson
![]() Georgetown University News | UMass wins $20m 'bench to bedside' grant Boston Globe (blog) ... Dr. John L. Sullivan, vice provost for research and professor of pediatrics and molecular genetics & microbiology at UMass, said in a statement. ... UMass med school gets $20M NIH grant to develop treatmentsWorcester Telegram |
FDA: Fat Pill Works, But Safety Is Still a Concern – FOXNews
By Dr. Matthew Watson
![]() RTT News | FDA: Fat Pill Works, But Safety Is Still a Concern FOXNews An experimental obesity pill from biotechnology company Vivus Inc appears to help people shed pounds, but concerns remain about its safety, US Food and Drug ... Vivus jumps ahead of FDA meeting on diet drugMarketWatch Vivus' fat pill works; safety a concern - FDA staffReuters India * FDA staff: Qnexa helps reduce weight, safety a concernReuters UK |
Rise of the Apes Loves (Brian) Cox – Inside Pulse (blog)
By Dr. Matthew Watson
![]() Dread Central | Rise of the Apes Loves (Brian) Cox Inside Pulse (blog) Rise of the Apes, which is still being called a tentative title by Fox, is set in present day San Francisco and would see genetic engineering lead to super ... Brian Cox Joins 'Rise Of The Apes'Hollywood.com Cox Chasing the APESMania Brian Cox Gets Evil In 'Rise Of The Apes'Latino Review Dread Central -Filmonic (blog) all 40 news articles » |
Brian Cox Enters Rise of the Apes – MovieWeb
By Dr. Matthew Watson
![]() WorstPreviews.com | Brian Cox Enters Rise of the Apes MovieWeb ... where man's own experiments with genetic engineering lead to the development of intelligence in apes and the onset of a war for supremacy. ... Brian Cox Ain't Monkeying Around in Planet of the Apes: Rise of the ApesDread Central Exclusive: Brian Cox to Abuse Primates in 'Rise of the Apes'TheWrap |
Two recent OA articles
By Dr. Matthew Watson
Two articles, with Open Access (OA) to the full text (PDF):
Putative cancer stem cells in malignant pleural mesothelioma show resistance to cisplatin and pemetrexed, Int J Oncol 2010(Aug); 37(2): 437-44. [PubMed citation].
Possible involvement of stem-like populations with elevated ALDH1 in sarcomas for chemotherapeutic drug resistance, Oncol Rep 2010(Aug); 24(2): 501-5. [PubMed citation].
Comment about these journals:
Spandidos Publications publishes six journals. Of these six, two are: International Journal of Oncology (2009 Impact Factor: 2.4) and Oncology Reports (2009 Impact Factor: 1.6). This publisher provides a hybrid open access option. The Information for Authors for all six journals includes, at the bottom of the page, this information: "Should authors prefer or require their article to be freely available as soon as it has been published, they may request open access immediately upon publication for a fee of EUR 450."
Monsanto And BASF Expand Their Biotechnology Collaboration – Benzinga
By Dr. Matthew Watson
![]() Commodity Surge (blog) | Monsanto And BASF Expand Their Biotechnology Collaboration Benzinga Monsanto and BASF announced yesterday the companies would expand their biotechnology research collaboration to include wheat. According to Jefferies & Co, ... BASF and Monsanto broad alliance of plant biotechnologyTimes News World (blog) BASF and Monsanto add wheat to biotech collaborationAgInfo.net (blog) BASF, Monsanto Expand R&D Collaboration To WheatFarm Chemicals International PR Newswire (press release) -domain-B all 49 news articles » |
International Stem Cell Corporation and Sankara Nethralaya Launch Collaboration to Develop Stem Cell-Based Treatment for Corneal Vision Impairment
By Dr. Matthew Watson
International Stem Cell Corporation (OTCBB:ISCO), http://www.internationalstemcell.com, and Sankara Nethralaya, http://www.sankaranethralaya.org, announced today commencement of a collaboration to develop ISCO's 'CytoCor™' stem cell-derived corneal tissue. The goal is to use CytoCor to treat corneal blindness and vision impairment. 'This is one more step in ISCO's stated plan of building its portfolio of therapeutic agents through strategic alliances throughout the world,' said Chairman, Ken Aldrich.
CytoCor consists of transparent human tissue derived from pluripotent human stem cells. These structures are produced in the laboratory and recent testing at Sankara Nethralaya and laboratories in the US has demonstrated a range of structural, biochemical and refractory properties characteristic of human cornea.
CytoCor may offer a first-in-class opportunity for high-quality, cost-efficient transplantation tissue for the 10 million people world-wide suffering from corneal vision impairment, particularly in India and the rest of Asia, as well as in Europe. Standardized tissues derived from pluripotent stem cells, such as the CytoCor tissue, could eliminate the current problem that corneal tissue derived from donors may harbor diseases that could be transferred from the donor to the recipient. It may also provide a much needed alternative to the use of live and extracted animal eyes in the $500+million market for safety testing of drugs, chemicals and consumer products.
According to Professor Dr. S. Krishnakumar, 'Sankara Nethralaya is dedicated to the development and application of new state-of-the-art ophthalmic technologies. The need for high-volume, high-quality human corneal tissue is substantial, not only in India but across Asia and much of Europe. We appreciate the opportunity to join ISCO in their pursuit to create a new standard of care for the treatment of human corneal disease.' Initially, Dr. Krishnakumar and his team will be using the CytoCor tissue in preclinical studies to explore the ability of the tissue to withstand sutures and bio-compatible glues in order to validate the potential of the tissue for use in animal or human clinical trials.
According to Dr. Geetha Krishnan Iyer, who is involved in the management of ocular surface disease at Sankara Nethralaya, 'The team at Sankara Nethralaya is pleased to collaborate with ISCO on stem cell-derived corneal tissue. In vitro studies to evaluate safety and efficacy of the tissue, as well as surgical feasibility tests will be carried out, following which there could be clinical application in lamellar keratoplasty using the above mentioned tissue. With improvements in surgical techniques over the past few years, the indications for anterior lamellar keratoplasty have expanded significantly. With high demand for donor corneal tissue for the same but limited availability, there is definitely scope for utilizing ISCO's corneal tissue following relevant tests.'
Jeffrey Janus, Senior VP of Operations at ISCO, states: 'This collaboration with the excellent team of scientists and clinicians at Sankara Nethralaya has already proven to be productive. Sankara's ophthalmology expertise and ISCO's cell culture capabilities constitute a perfect match to perfect and advance CytoCor tissue towards future use in treating corneal disease and injuries.'
ABOUT INTERNATIONAL STEM CELL CORPORATION (ISCO.OB):
International Stem Cell Corporation is a California-based biotechnology company focused on therapeutic and research products. ISCO's core technology, parthenogenesis, results in creation of pluripotent human stem cells from unfertilized oocytes (eggs). These proprietary cells avoid ethical issues associated with use or destruction of viable human embryos and, unlike all other major stem cell types, can be immune matched and be a source of therapeutic cells with minimal rejection after transplantation into hundreds of millions of individuals across racial groups. ISCO also produces and markets specialized cells and growth media for therapeutic research worldwide through its subsidiary Lifeline Cell Technology and is developing a line of cosmeceutical products via its subsidiary Lifeline Skin Care. ISCO is advancing novel human stem cell-based therapies where cells have been proven to be efficacious but traditional small molecule and protein therapeutics have not. More information is available at ISCO's website, http://www.internationalstemcell.com.
To subscribe to receive ongoing corporate communications please click on the following link: http://www.b2i.us/irpass.asp?BzID=1468&to=ea&s=0.
FORWARD-LOOKING STATEMENTS
Statements pertaining to anticipated technological developments and therapeutic applications, the potential benefits of collaborations, and other opportunities for the company and its subsidiaries, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical fact (including, but not limited to statements that contain words such as "will," "believes," "plans," "anticipates," "expects," "estimates,") should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products and the management of collaborations, uncertainty in the results of clinical trials or regulatory approvals, need and ability to obtain future capital, application of capital resources among competing uses, and maintenance of intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the company's business, particularly those mentioned in the cautionary statements found in the company's Securities and Exchange Commission filings. The company disclaims any intent or obligation to update these forward-looking statements.
Key Words: Stem Cells, Biotechnology, Parthenogenesis
International Stem Cell Corporation
Kenneth C. Aldrich, Chairman
760-940-6383
kaldrich@intlstemcell.com
Or
Brian Lundstrom, President
760-640-6383
bl@intlstemcell.com
BASF and Monsanto broad alliance of plant biotechnology – Times News World (blog)
By Dr. Matthew Watson
![]() Commodity Surge (blog) | BASF and Monsanto broad alliance of plant biotechnology Times News World (blog) BASF SE and Monsanto want to expand their cooperation in biotechnology increase yields of crops and invest in expansion of cooperation in addition, ... BASF, Monsanto Expand R&D Collaboration To WheatFarm Chemicals International BASF Plant Science and Monsanto to Expand Their Collaboration in Maximizing ...PR Newswire (press release) BASF, Monsanto to invest additional $1 billion in joint crop researchdomain-B |
Sangamo BioSciences Announces Nature Biotechnology Study Demonstrating the Use … – PR Newswire (press release)
By Dr. Matthew Watson
![]() Minyanville.com | Sangamo BioSciences Announces Nature Biotechnology Study Demonstrating the Use ... PR Newswire (press release) The data reported in the Nature Biotechnology publication replicate these findings for a ZFN-based treatment in a preclinical model. ... Sangamo's Technology Offers Confidence to InvestorsMinyanville.com |
Mother’s diet, genes raise birth defect risk: study – Reuters
By Dr. Matthew Watson
![]() Reuters India | Mother's diet, genes raise birth defect risk: study Reuters The British researchers, whose findings were published in the journal Human Molecular Genetics, compared healthy mice with those lacking a gene called ... Maternal diet and genes interact to affect heart developmentEurekAlert (press release) Pregnant mum's high-fat diet 'bad for baby's heart'Thaindian.com |
McDonald’s threatened with lawsuit over toys in Happy Meals
By Dr. Matthew Watson
The Los Angeles Times recently reported that the Center for Science in the Public Interest (CSPI) is planning to sue fast-food giant McDonald's if the company does not comply with its demands to remove toys from "Happy Meals". CSPI claims that marketing unhealthy food with toys is contributing to the childhood obesity epidemic and should be stopped immediately.
The announcement by CSPI comes just weeks after a California county banned not only toys but all other promotions aimed at children that involve McDonald's Happy Meals. By doing this, the county believes that children will be less attracted to fatty foods that are high in salt and calories.
According to the same article, back in April, Santa Clara County, California, also banned toy promotions from fast food meals sold in unincorporated parts of the county.
Spokesmen from McDonald's denied that Happy Meals are inherently unhealthy, citing the fact that the meals are of an appropriate size and that children have the option to swap out the fries and soda for apples and juice. They also explained that giving away toys with children's meals is part of the fun of a family dining experience.
Since 2008 when apples were first introduced as an option in Happy Meals, customers have ordered them more than 100 million times, illustrating that when given healthier options, customers often choose them for their children instead. Read more...
Cold symptoms
A not so rare but frequently disregarded Metabolic Disorder – Pyrroluria
By Dr. Matthew Watson
The abbreviation KPU stands for pyrroluria, which is a frequently disregarded metabolic disorder that may cause numerous unspecific symptoms. However, it is comparatively easy to treat. In general, KPU (a.k.a. pyrroluria, malvaria, or HPU) is a genetically determined anomaly of hemal production (an aspect of blood formation) which causes increased hemal pyrrole concentrations.
Normally, this substance does not circulate freely in the blood but is bound by bile acid and excreted through the intestines. In KPU-cases, however, crypto pyrrole is increasingly excreted in the urine – unfortunately along with vitamin B6, zinc, and manganese which the body lacks due to this process.
In combination with increased stress (e.g. acute viral rhinopharyngitis, burns, injuries/accidents, intestinal infections, or psychic stress) this causes a wide range of symptoms, such as:
disturbances of memory and sleep, erratic mood swings, depression, hair loss, proneness to infections, and chapped skin. There is also a possible relation to ADHD with children and juveniles. Read more...
Immunice for Immune Support
Acupuncture May Trigger Natural Painkiller
By Dr. Matthew Watson
(HealthDay News) -- The needle pricks involved in acupuncture may help relieve pain by triggering a natural painkilling chemical called adenosine, a new study has found.
The researchers also believe they can enhance acupuncture's effectiveness by coupling the process with a well-known cancer drug -- deoxycoformycin -- that maintains adenosine levels longer than usual.
"Acupuncture has been a mainstay of medical treatment in certain parts of the world for 4,000 years, but because it has not been understood completely, many people have remained skeptical," lead author Dr. Maiken Nedergaard, co-director of the Center for Translational Neuromedicine at the University of Rochester Medical Center, said in a news release. "In this work, we provide information about one physical mechanism through which acupuncture reduces pain in the body." Read more...
Neurological and Immune Reactive Conditions Affecting Kids
By Dr. Matthew Watson
Neurological and Immune Reactive Conditions Affecting Kids: The mercury connection to neurological pervasive developmental disorders(autism, schizophrenia, dyslexia, ADD,childhood depression, learning disabilities, OCD, etc.)and developmental immune conditions (eczema, asthma, and allergies)Bernard Windham- Chemical Engineer
http://www.home.earthlink.net/~berniew1/kidshg.html
The incidence of neurotoxic, allergic, and immune reactive conditions such as autism, schizophrenia, ADD, dyslexia, allergies, asthma, eczema, psoriasis, childhood diabetes, etc. have been increasing rapidly in recent years. A recent report by the National Research Council found that 50% of all pregnancies in the U.S. are now resulting in prenatal or postnatal mortality, significant birth defects, developmental disabilities or otherwise chronically unhealthy babies(3). Read more...
Sweet and Natural?
By Dr. Matthew Watson
What is tagatose? I heard it mentioned as a sugar substitute, but it's a new one on me. Is it safe or just another sweetener we should avoid? And what's the latest word on the safety of Splenda?
Tagatose is a natural sweetener that is 92 percent as sweet as sugar, but has only one-third of the calories. The FDA approved its use in foods and beverages in 2001. You'll see it in packaged cereals and diet sodas, and it is also used in mouthwash, toothpaste, lipstick and in various drugs, both prescription and over-the-counter. Read more...
Ayurtox for Body Detoxification